You just read:

European Medicines Agency accepts submission of GSK's Marketing Authorisation Application for Zejula (niraparib) in first-line maintenance treatment for women with platinum-responsive advanced ovarian cancer

News provided by

GlaxoSmithKline plc

Feb 27, 2020, 04:00 ET